Biologics manufacturing facility construction
Key Statistics
PM Group Office
30,000 sq.m.

MSD has completed its new cutting edge biotechnology facility in Swords, Co. Dublin. The development will play a pivotal role in the manufacture of MSD’s biologics-based medicines, including in the area of immuno-oncology. It will also expand MSD’s current internal network of biologics drug substance manufacturing plants.

The project won the 2020 CURT Project Excellence Award (Projects over $1Bn category). It was also winner of MSD’s 2019 GES (Global Engineering Services) Safety Award for “Best Large Project” and 2019 “Best Construction Innovation” award.

Full manufacturing operations are expected to begin in 2021.


Excellence in project delivery

The MSD Biotech project, for which EPCMCQV was managed by a JV of PM Group and Jacobs Engineering, has set a new benchmark with respect to excellence in project delivery for biopharmaceutical facilities.

From the outset, the project challenge was to complete OQ of the first Bioreactor train within 30 months from concept kick-off - some 6 months faster than previous completions in the world for similar projects. In achieving the schedule milestones, over 4.8 million hours were worked onsite without an OSHA Lost Time Incident (LTI). This required the conscious, continuous focus on planning, coordination and cooperation of all stakeholders.

Peak construction saw 1,825 people on site with over 7,000 inductions completed. The leading Indicator driven EHS Management System, where PM Group were the PSCS, achieved a TRIR of 0.22 and DART of 0.0.

Digital turnover system

A fully digitalised turnover system saw construction turnover performance set new industry records. With 1281 systems reaching mechanical completion, averaging 38 systems per week over the 7-month peak turnover period.